Browse the evidence

Consuming an unprocessed diet reduces energy intake because participants preferentially select low-energy-dense components (fruits/vegetables) to meet micronutrient requirements, a behavior termed 'micronutrient deleveraging' that limits total caloric intake despite larger meal mass.

To manage energy intake without counting calories, prioritize unprocessed foods that are rich in micronutrients, such as fruits and vegetables. Your body may naturally limit your calorie intake if it prioritizes meeting its micronutrient needs, a process the authors call 'micronutrient deleveraging.' By choosing these foods, you may consume larger volumes of food with fewer calories, satisfying your nutritional requirements without overconsuming energy.

Early weight loss trajectory (first 14 days) and recording frequency can predict long-term weight loss patterns, with shallow initial loss and infrequent logging predicting a 'plateau-then-increase' pattern.

Track your weight daily for the first two weeks. If you aren't losing weight or are skipping logs, you are statistically likely to hit a plateau and regain weight later. Use this early data to adjust your habits immediately rather than waiting months to see if it works.

Perceived success in weight loss maintenance is a stronger predictor of satisfaction and continued physical activity engagement than quantitative weight loss metrics alone.

Don't just focus on the scale. If you don't *feel* like you've succeeded, you're less likely to stay active and satisfied, even if you've lost weight. Align your goals with how you want to feel and function, not just a percentage of weight loss.

GLP-1 receptor agonists (specifically high-dose liraglutide) prevent the progression from prediabetes to type 2 diabetes in obese individuals.

If you have prediabetes and are overweight, talk to your doctor about GLP-1 medications like liraglutide. They can significantly reduce your risk of developing full-blown type 2 diabetes.

Incretin-based treatments (semaglutide, dulaglutide) are effective and safe in adolescents with obesity or type 2 diabetes.

For teenagers with obesity or type 2 diabetes, weekly injections of semaglutide or dulaglutide can significantly improve weight and blood sugar control. Side effects like nausea are common but usually mild and go away quickly.

Shorter duration of hypertension history is an independent predictor of hypertension remission following Roux-en-Y gastric bypass surgery, with each additional year of history decreasing the odds of remission by approximately 15%.

If you are considering bariatric surgery to get off blood pressure medication, the length of time you have had high blood pressure matters. The study shows that for every year you wait, your chances of successfully stopping medication drop by about 15%. This suggests that addressing hypertension early, or seeking surgical options sooner rather than later, offers the best chance for remission.

Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring systems improve glycemic control and reduce hypoglycemia risk in patients with Type 2 Diabetes, particularly those on insulin therapy.

If you have Type 2 Diabetes and are on insulin, ask your doctor about Continuous Glucose Monitoring (CGM) or Flash Glucose Monitoring systems. These devices provide real-time data on your blood sugar levels and trends, helping you and your doctor adjust your insulin doses more precisely and safely, reducing the risk of dangerous lows.

GLP-1 receptor agonists (Liraglutid, Semaglutid) and dual agonists (Tirzepatid) produce significant weight loss (16-20%) and reduce cardiovascular/renal complications in Type 2 Diabetes, but their long-term efficacy and cost-effectiveness remain unproven.

If lifestyle changes are insufficient, GLP-1 drugs like Semaglutid offer significant weight loss (up to 20%) and heart/kidney benefits, especially for diabetics. However, they are expensive, require injections, and likely need to be taken indefinitely to maintain weight loss. Discuss cost and long-term commitment with your doctor.

SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100 demonstrate varying degrees of efficacy in weight management, with SGLT-2 inhibitors showing mild but significant weight loss in non-diabetic obese patients.

Several other medications besides GLP-1 agonists can help with weight loss, including SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100. Their effectiveness varies, with some showing significant weight loss and others showing mild but significant benefits. These options provide additional choices for patients who may not be candidates for or respond poorly to GLP-1 agonists.

SGLT2 inhibitors (specifically enavogliflozin and sotagliflozin) provide superior glycemic control and cardiovascular/renal benefits compared to placebo or standard care in patients with type 2 diabetes, with sotagliflozin specifically indicated for heart failure.

If you have type 2 diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like sotagliflozin or enavogliflozin. These oral drugs are now prioritized in guidelines because they protect your heart and kidneys while lowering blood sugar.

GLP-1 receptor agonists (specifically semaglutide) produce substantial, sustained weight loss and improve health status in patients with heart failure with preserved ejection fraction (HFpEF).

For patients with HFpEF and obesity, GLP-1 agonists like semaglutide are a potent tool for weight loss and improving heart function. This treatment, combined with dietary advice, can lead to significant health improvements. Discuss this option with your cardiologist, especially if other weight loss methods have been difficult to sustain.

Visceral obesity is a critical risk factor for cardiovascular disease, often present in individuals with normal BMI, leading to underestimation of cardiovascular risk in clinical practice.

Don't rely solely on BMI. If you have a family history of heart disease, ask for a waist circumference measurement or visceral fat assessment, as 'normal weight' obesity can still cause heart attacks.

Tirzepatide (dual GLP-1/GIP agonist) produces superior weight loss compared to semaglutide in patients with type 2 diabetes.

For patients with type 2 diabetes, tirzepatide (5-15 mg weekly) may offer better weight loss (8.5-12.4%) than semaglutide (6.7%). However, it is not yet registered for obesity treatment in Poland, so access may be limited.

Bariatric surgery is the most effective, sustainable, and generally safe therapy for severe obesity (BMI ≥ 35 kg/m²) when lifestyle and pharmacological treatments have failed.

For severe obesity (BMI ≥ 35) where lifestyle and drug treatments have failed, bariatric surgery is the most effective and sustainable option. It is indicated for BMI > 30 with type 2 diabetes. Risks must be carefully weighed against benefits, and lifelong follow-up is required.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than Semaglutide in patients with type 2 diabetes.

If you have type 2 diabetes and obesity, ask your doctor about Tirzepatide. It is a once-weekly injection that combines two hormones to help you lose more weight than Semaglutide. It starts at a low dose and increases every few weeks to reach the maximum dose.

Bariatric surgery (Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass) provides effective and sustainable weight loss, with Roux-en-Y showing greater long-term excess weight loss but higher morbidity.

If you have severe obesity (BMI >40 or >35 with health issues), surgery is a highly effective option. Gastric Bypass leads to more weight loss than Sleeve Gastrectomy but has higher risks. Discuss the trade-offs with your surgeon.

Both intensive behavioral group intervention and brief individual counseling result in small, similar weight loss over 5 years, suggesting that regular follow-up and person-centered care may promote weight maintenance.

Regular medical check-ins and basic dietary advice can help maintain weight in middle age. You do not necessarily need complex programs to achieve modest, sustainable results.

Tirzepatide provides significant cardiovascular, hepatic, and renal benefits in obese patients, including improved lipid profiles, reduced blood pressure, and potential protection against NAFLD/NASH and CKD progression.

Beyond weight loss, Tirzepatide improves heart health by lowering blood pressure and cholesterol, and may protect the liver (NAFLD/NASH) and kidneys (CKD). These benefits are observed alongside weight loss but may also stem from direct hormonal effects.

Maintaining weight loss is significantly harder than losing it due to physiological mechanisms (AgRP neuron activation, leptin resistance) that drive weight regain, requiring sustained energy deficit and often pharmacological support.

Expect your body to fight back after you lose weight. Biological mechanisms like increased hunger signals (AgRP neurons) will try to restore your previous weight. To counter this, you need a sustained energy deficit, possibly aided by medication, and consistent lifestyle habits. Maintenance is a biological battle, not just a mental one.

Dietary fiber intake must be accompanied by adequate water intake to prevent constipation, a common adverse event of anti-obesity medications.

When taking weight loss medications, increase your intake of fruits, vegetables, and whole grains for fiber, but you MUST drink more water. Without enough fluid, high fiber can cause constipation, which is already a common side effect of these drugs.

Early combination therapy using low-hypoglycemia-risk agents (e.g., SGLT2 inhibitors or GLP-1 receptor agonists) combined with metformin at diagnosis is more effective than sequential stepwise therapy at maintaining glycemic targets and minimizing diabetes-related complications.

If you have just been diagnosed with Type 2 Diabetes, ask your doctor about starting with a combination of Metformin and another modern drug (like an SGLT2 inhibitor or GLP-1 agonist) right away, rather than waiting for your blood sugar to rise again. This approach keeps your blood sugar closer to normal levels for longer and protects your heart and kidneys better than starting with just one drug.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) produce significant weight loss (up to 24.2%) and improve metabolic parameters, but they significantly increase the risk of delayed gastric emptying and perioperative pulmonary aspiration.

If you take semaglutide or tirzepatide, tell your anesthesiologist. These drugs slow down your stomach, which increases the risk of vomiting and inhaling stomach contents during surgery, even if you feel fine. You may need to stop the drug a week before surgery, or your procedure might be delayed. Do not assume standard fasting rules are enough.

Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.

Tirzepatide may help protect your kidneys by slowing the decline in kidney function and reducing protein in the urine, which is beneficial for long-term kidney health in diabetes.

In patients with heart failure and reduced ejection fraction (HFrEF), a BMI greater than 27 kg/m² is associated with significantly higher risks of cardiovascular mortality, heart failure hospitalization, and composite adverse outcomes compared to a BMI of 24–27 kg/m².

If you have heart failure with reduced ejection fraction, maintaining a BMI between 24 and 27 kg/m² is associated with better survival and fewer hospitalizations than having a BMI over 27. This is especially true if your heart failure is caused by coronary artery disease (ischemic). You should discuss weight management strategies with your cardiologist, as higher BMI may increase your risk of cardiovascular death and hospitalization.